Drug Profile
Research programme: dyslipidaemia oral therapeutics - ABIONYX Pharma
Alternative Names: HDL receptor enhancerLatest Information Update: 11 Sep 2019
Price :
$50
*
At a glance
- Originator Cerenis Therapeutics
- Developer ABIONYX Pharma
- Class Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; GPR109A receptor agonists; GPR109B receptor agonists; HMG-CoA reductase inhibitors; Lipoprotein receptor agonists; Nitric oxide stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dyslipidaemias in Unknown (PO)